IMPACT-2 (Methylone for PTSD)

  • Research type

    Research Study

  • Full title

    An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD IMPACT-2 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])



  • Contact name

    Amanda Jones

  • Contact email

  • Sponsor organisation

    Transcend Therapeutics

  • Research summary

    Methylone is a new and potentially effective treatment option for participants with post traumatic stress disorder (PTSD). This is a two-part study to evaluate the safety and efficacy of methylone for the treatment of PTSD. Part A is an open-label assessment in up to 15 participants with PTSD; Part B is a randomized (1:1), double-blind, placebo-controlled assessment in up to 64 participants. After completion of Part A, enrolment for Part B will begin.
    Eligible participants are 18 to 70 years of age with a diagnosis of PTSD. Each participant will attend a total of 17 visits, including 3 weekly dosing sessions, over the up to 13 week study period.

  • REC name

    London - Brent Research Ethics Committee

  • REC reference


  • Date of REC Opinion

    27 Oct 2023

  • REC opinion

    Further Information Favourable Opinion